At SIMOS 2025, JIER Biochemical made a strong impact by presenting its latest advances in peptide-based personalized therapy. As a result, the company further strengthened its role in global translational medicine and oncology innovation.

During the opening ceremony, leading experts emphasized the need to break down barriers between disciplines. This approach aims to move research faster from the lab to the patient. In this context, peptide drugs are becoming a key driver in cancer immunotherapy and precision nuclear medicine.

SIMOS 2025 Peptide Innovation Trends: Personalized Therapy Takes the Lead

At the conference, peptide drugs stood out due to their clear advantages:

• High targeting ability, which improves treatment precision
• Low toxicity, reducing side effects for patients
• Easy modification, enabling flexible drug design

Therefore, peptides are now widely used in:

• Tumor immunotherapy
• Radiopharmaceuticals
• Precision oncology treatments

Because of these strengths, the global demand for peptide CDMO services continues to grow rapidly.

JIER Biochemical GMP Peptide Platform: High Quality & Fast Delivery

With 27 years of experience in solid-phase peptide synthesis, JIER Biochemical introduced its advanced GMP-level platform.

1. High Production Capacity for IND Applications

• Single batch synthesis scale reaches 10 mmol
• Impurity level controlled at ≤0.3%

As a result, these standards fully support IND filing requirements and early-stage clinical development.

2. Fast Turnaround for Personalized Therapy

• 24/7 continuous peptide synthesis
• Delivery in as fast as a few days

This significantly shortens the timeline from design to clinical use.

3. Modular Integrated Production Line

Moreover, JIER offers a flexible production system that can deliver:

• Neoantigen long peptides
• PDC linker-payload components
• Radiopharmaceutical precursors

In other words, one production line can support both immunotherapy and radiotherapy pipelines.

CDMO + CRO Integrated Services for Global Biotech Partners

In addition to manufacturing, JIER Biochemical provides full-service support:

• CDMO services for peptide drug production
• CRO services for early-stage research and validation
• Regulatory support for clinical applications

Furthermore, the Beidaihe New Area “Personalized Tumor Therapy Base” is progressing quickly. Once operational, it will enable a complete closed-loop system:

Sample → Neoantigen Design → Peptide Synthesis → QC Release → Clinical Infusion

This end-to-end model will greatly improve efficiency and scalability for global partners.

Strategic Partnerships Driving Peptide Drug Innovation

During SIMOS 2025, JIER Biochemical signed multiple agreements with research institutions, including:

• Neoantigen peptide clinical translation collaborations
• Peptide nuclear medicine linker technology co-development

These partnerships will accelerate:

• Early-stage clinical trials
• Drug registration processes
• Commercialization of innovative peptide therapies

As a result, JIER continues to expand its global innovation network.

JIMERJIAER Peptide Skincare Products: Expanding Peptide Applications

While JIER focuses on pharmaceutical peptides, its brand JIMERJIAER applies peptide technology to skincare.

Key Product Lines

• Anti-aging peptide serums for wrinkle reduction
• Hydrating creams for deep skin repair
• Brightening solutions for even skin tone

B2B Advantages

• OEM/ODM customization for global brands
• Stable supply backed by advanced peptide synthesis
• Compliance-ready formulations for international markets

Therefore, JIMERJIAER bridges the gap between biomedical peptide research and commercial skincare applications.